Skip to main content
Equibles
OGEN logo

OGEN · Oragenics Inc · Metrics

Track OGEN — free

Use OGEN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OGEN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.41 -0.02 (-4.88%) At close · Oct 21
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on these factors, there is substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$1.96M
Shares
4.51M
Volume · Oct 21 5364 Avg daily vol (3M) 29.39K

OGEN metrics

69 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.41
Market cap
$1.96M

Price action

20 metrics
Price change (1W)
-2.9%
Price change (30D)
-16.4%
Price change (3M)
-19.6%
Price change (6M)
-34.2%
Price change (YTD)
-44.4%
Price change (1Y)
-67.9%
Trailing year
Price change (5Y)
—
52-week high
$1.37
52-week low
$0.42
Change from 52-week high
-68.3%
Change from 52-week low
+2.8%
Annualized volatility
66.9%
Annualized volatility (3M)
46.3%
Beta
1.4
RSI (14D)
37.4
Price vs SMA 50
-12.7%
Price vs SMA 200
-30.7%
Avg volume (3M)
29,848
Relative volume
0.5
Average dollar volume
$15,098

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
4.51M

Valuation

12 metrics
P / E (TTM)
0.4
Trailing earnings · reciprocal yield 255.8%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
50.6×
reciprocal yield 2.0%
P / book
0.5
reciprocal yield 192.8%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-529.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-55,519.9%
Trailing 12 months
Net margin
-54,858.1%
Gross profit (TTM)
$0
Operating profit (TTM)
−$10.47M
Net income (TTM)
−$10.08M
Trailing 12 months
Diluted EPS (TTM)
$1.11
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.52
Gross profit per diluted share (TTM)
$-1.62
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
$-271.19
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.94

Growth

11 metrics
Revenue growth YoY
-71.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$37,653
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+505.1%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-274.7%
Return on assets
-183.6%
Debt / equity
0.0
Current ratio
—
EBITDA (TTM)
−$20.88M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
-561.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$3.86M
Latest balance sheet
Cash & equivalents
$3.86M
Total assets
$5.49M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$10.21M
Capital expenditures (TTM)
$127,519
R&D (TTM)
$3.42M
SG&A (TTM)
$3.91M
Stock compensation (TTM)
$652,848
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
18
13F filer change QoQ
-3
Institutional ownership
1.5%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
0.4%
Private-fund adviser ownership
0.0%
Active holders' share change QoQ
-65.1%
Holder tenure
2.6
Price vs estimated holder cost
-14.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.4%

Short interest

3 metrics
Short interest
18.7%
Latest settlement · 24.9 days to cover
Days to cover
24.9d
Short-squeeze score
75 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1174940 CUSIP 684023609 13F (30d) 2 filings 2 filers Visit website Investor relations